Procyon Advisors LLC Sells 20,904 Shares of Becton, Dickinson and Company $BDX

Procyon Advisors LLC cut its holdings in Becton, Dickinson and Company (NYSE:BDX) by 88.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,679 shares of the medical instruments supplier’s stock after selling 20,904 shares during the quarter. Procyon Advisors LLC’s holdings in Becton, Dickinson and Company were worth $461,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in BDX. Saudi Central Bank bought a new stake in Becton, Dickinson and Company in the first quarter valued at about $26,000. Smallwood Wealth Investment Management LLC bought a new position in Becton, Dickinson and Company during the first quarter worth about $27,000. REAP Financial Group LLC grew its position in shares of Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 55 shares during the period. Alpine Bank Wealth Management bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at about $29,000. Finally, Cornerstone Planning Group LLC raised its position in shares of Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 99 shares during the period. Institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the sale, the executive vice president directly owned 4,887 shares of the company’s stock, valued at $881,077.23. This represents a 19.52% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 2,965 shares of company stock worth $551,536. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Trading Up 0.5%

Shares of BDX stock opened at $188.44 on Friday. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $54.01 billion, a P/E ratio of 33.89, a P/E/G ratio of 1.51 and a beta of 0.27. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The stock’s fifty day simple moving average is $187.42 and its 200 day simple moving average is $190.65.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company had revenue of $5.51 billion for the quarter, compared to analysts’ expectations of $5.50 billion. During the same period in the previous year, the business posted $3.50 earnings per share. The business’s quarterly revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company’s payout ratio is 74.82%.

Wall Street Analysts Forecast Growth

BDX has been the topic of a number of recent analyst reports. Piper Sandler reissued a “neutral” rating and set a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Wells Fargo & Company raised their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research report on Friday, August 8th. Argus lifted their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday. Citigroup cut Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and lowered their target price for the stock from $217.00 to $185.00 in a research note on Thursday, May 22nd. Finally, Barclays cut their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 3rd. Four research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $213.30.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.